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the frequency of reoperation and other complications
such as thromboembolism and prosthetic valve endo-
carditis.1-8 Although Doppler echocardiography is gen-
erally accepted as the method of choice for monitoring
valve function in individual patients with suspected
prosthetic dysfunction, few systematic long-term fol-
low-up studies have been conducted with echocardiog-
raphy after valve replacement with a bioprosthesis.9,10 It
is of the utmost concern, and probably at present the
most important issue, to determine the functional out-
come for patients with bioprostheses, both to optimize
the time of reoperation and to make a fair estimation of
the advantages and disadvantages of bioprostheses. 
We have already demonstrated the 10-year actuarial
freedom from valve-related mortality to be high, 98%
for patients with aortic and 95% for those with mitral
Biocor prostheses.6,7 The aims of this study were to
delineate bioprosthetic and cardiac function among
P orcine bioprostheses have been used frequently inrecent decades and numerous clinical reports have
been published. Calcifications and cusp tears often
develop within 10 to 15 years, necessitating a reopera-
tion. Several long-term follow-up studies have reported
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patients with this porcine bioprosthesis inserted over a
10-year period and to determine echocardiographic
accuracy for selection of patients requiring reoperation.
Patients and methods
Study patients. During a 10-year period from 1983 to
1993, 619 patients underwent aortic valve replacement and
137 patients underwent mitral valve replacement with the
Biocor prosthesis, a glutaraldehyde-preserved, zero pressure–
fixed, stented porcine bioprosthesis (Fig 1). These 756
patients were studied in terms of mortality and morbidity
until January 1993.6,7 All patients who had a reoperation dur-
ing the follow-up time (41 with an aortic and 10 with a mitral
bioprosthesis) were followed up echocardiographically from
initial detection of a suspected lesion to reoperation. In addi-
tion, 446 patients with aortic and 74 with mitral bioprosthe-
ses were alive at the end of this period and had not been reop-
erated on or lost to follow-up. Doppler echocardiographic
investigations performed until July 1994 (in almost 60% of
the patients) are presented; if multiple, the last one was cho-
sen for this report. The mean follow-up time was almost 5
years for the group with aortic bioprostheses (52 months, n =
120 > 5 years) and almost 6 years for the group with mitral
bioprostheses (71 months, n = 28 > 5 years). There is no def-
inite rule in our region that specifies when or how often
Doppler echocardiographic investigations should be per-
formed. Because almost all the patients lacked symptoms, the
selection of patients for Doppler echocardiography has been
random. These patients were similar to the entire group in
terms of sex, preoperative diagnoses, additional coronary
bypass surgery, and postoperative New York Heart Associ-
ation functional classes, although they were somewhat
younger than the group as a whole (Table I).
Doppler echocardiography. Transthoracic Doppler echo-
cardiography was the method used in all patients. Previous
collaboration on recording and interpretational techniques
has demonstrated that the evaluations are comparable at the
different institutions.
M-mode echocardiography was performed according to the
recommendations of the American Society of Echocardiogra-
phy.11 Measurements of the atrial diameter (normal ≤ 4.0
cm), septal and posterior walls (normal ≤ 1.2 cm), as well as
the dimension of the left ventricular cavity (normal dimen-
sion at end-diastole ≤ 5.8 cm), were made. Left ventricular
volumes, stroke volume, and ejection fraction were calculat-
ed by the formula described by Teichholtz and associates.12
Left ventricular mass index was calculated as previously
described (normal ≤ 140 g/m2).13 The Doppler assessment of
valvular leakage was graded as 0 when absent and as 4 when
maximum regurgitation, with the other grades dispersed in
between,14 integrating information from color and continu-
ous-wave Doppler echocardiography, as well as the effects on
cardiac dimensions. Valve gradients (P) were calculated from
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Fig 1. Overview of the total cohort. The patients who are
highlighted are presented in this study. AVR, Aortic valve
replacement; MVR, mitral valve replacement. *Includes 9
valve-related deaths. †Includes 4 valve-related deaths. 
Table I. Baseline characteristics
Aortic valve Mitral valve 
replacement replacement
Non-echo Echo Non-echo Echo
Total No. of patients 183 263 32 42
Female (%) 37 36 56 52
Age
Mean (yr) 70.0 63.7 65.6 58.4
Distribution (%)
21-30 yr 0 4 0 2
31-40 yr 2 6 3 10
41-50 yr 4 8 6 7
51-60 yr 8 13 19 33
61-70 yr 25 26 31 34
71-80 yr 52 41 38 14
81-90 yr 8 2 3 0
Aortic valve lesion (n)
Stenosis 134 183 — —
Regurgitation 20 48 — —
Mixed 29 32 — —
Mitral valve lesion (n)
Regurgitation — — 26 20
Stenosis + mixed — — 6 22
Angina pectoris 38 21 38 17
(CABG) (%)
Functional class 
distribution postop (%)
I 46 53 50 31
II 42 36 25 52
III 4 11 13 17
IV 0 0 0 0
Unknown 8 — 12 —
Distribution of valve 
sizes (%)
21 15 13 — —
23 30 31 — —
25 35 31 3 5
27 14 18 6 14
29 4 5 22 21
31 2 1 50 22
33 — 1 19 38
CABG, Coronary artery bypass grafting.
continuous-wave Doppler estimates of maximum velocity (v)
as P = 4 · v2. We used the peak gradient, which is always
higher than the mean gradient. In cases of mitral stenosis, we
calculated the gradient half-time from the early deceleration
slope. The left ventricular ejection time was obtained from
carotid pulse tracings and adjusted for heart rate (normal
adjusted value 90%-110%) and the a/H ratio (ratio of atrial
height to total apex cardiographic height) was assessed from
apex cardiograms as a measure of left ventricular distensibil-
ity (normal ≤ 15%).
Statistical analysis. Values are presented as the mean ±
standard error of the mean. Wilcoxon’s nonparametric paired
signed rank test was used to determine the significance of
changes between preoperative and follow-up measurements.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 116, Number 4
Mykén et al   601
Table II. Normal bioprosthetic valves
Mitral valve replacement 
Aortic valve replacement (n = 33)
(n = 242)
Mitral stenosis 
Time Aortic stenosis Aortic regurg Mixed lesion Mitral regurg + mixed lesions
Preop diagnoses (n = 168) (n = 45) (n = 29) (n = 18) (n = 15)
NYHA class Preop 2.8 ± 0.05 2.7 ± 0.1 3.1 ± 0.2 3.1 ± 0.1 2.9 ± 0.1
Postop 1.5 ± 0.05‡ 1.5 ± 0.1‡ 1.8 ± 0.2‡ 1.7 ± 0.1‡ 1.9 ± 0.2†
Maximum gradient (mm Hg) Preop 96.5 ± 2.7 25.1 ± 4.0 57.8 ± 4.0 — 23.0 ± 2.4
Postop 28.7 ± 1.0‡ 27.7 ± 2.0 30.1 ± 2.4‡ 11.5 ± 1.1 13.3 ± 1.1
AR (grade) Preop 0.9 ± 0.1 3.4 ± 0.1 2.4 ± 0.2 — —
Postop 0.5 ± 0.1‡ 0.5 ± 0.1‡ 0.5 ± 0.1‡ — —
MR (grade) Preop — — — 3.4 ± 0.2 1.8 ± 0.3
Postop — — — 0.4 ± 0.2‡ 0.1 ± 0.05
Mitral T 0.5 (ms) Preop — — — — 254.6 ± 42.2
Postop — — — 122.8 ± 7.3 96.7 ± 9.0†
RVp (mm Hg) Preop 37.5 ± 2.5 41.3 ± 5.1 — 56.8 ± 7.1 63.9 ± 15.1
Postop 33.4 ± 1.4 26.0 ± 3.5 36.3 ± 3.9 40.3 ± 9.1 34.5 ± 2.8
LVd (cm) Preop 5.2 ± 0.1 7.1 ± 0.2 6.1 ± 0.2 6.6 ± 0.3 5.1 ± 0.3
Postop 5.0 ± 0.1 5.4 ± 0.1‡ 5.3 ± 0.2 5.5 ± 0.3† 4.7 ± 0.2
LVs (cm) Preop 3.5 ± 0.1 4.8 ± 0.2 4.5 ± 0.2 4.3 ± 0.3 3.5 ± 0.2
Postop 3.4 ± 0.1 3.5 ± 0.2‡ 3.9 ± 0.2 3.7 ± 0.4 3.3 ± 0.3
LA (cm) Preop 4.5 ± 0.1 4.3 ± 0.1 4.9 ± 0.2 6.0 ± 0.3 5.9 ± 0.3
Postop 4.4 ± 0.1 4.2 ± 0.1 4.9 ± 0.2 5.3 ± 0.3 5.5 ± 0.4
IVS (cm) Preop 1.8 ± 0.05 1.3 ± 0.1 1.5 ± 0.05 1.3 ± 0.1 1.2 ± 0.3
Postop 1.4 ± 0.05‡ 1.3 ± 0.1 1.6 ± 0.1 1.1 ± 0.1 1.1 ± 0.1
PW (cm) Preop 1.5 ± 0.05 1.2 ± 0.05 1.3 ± 0.03 1.3 ± 0.3 —
Postop 1.2 ± 0.03† 1.1 ± 0.05 1.3 ± 0.1 1.0 ± 0.1 1.1 ± 0.1
LVET (%) Preop 115.6 ± 1.0 114.0 ± 2.4 113.1 ± 3.1 92.8 ± 5.3 97.0 ± 6.9
Postop 101.1 ± 1.2‡ 95.9 ± 4.8 101.0 ± 5.5 90.8 ± 2.7 98.5 ± 1.5
a/H ratio (%) Preop 18.1 ± 1.0 19.8 ± 2.6 19.1 ± 3.2 — —
Postop 14.6 ± 1.6 10.5 ± 3.5 20.5 ± 7.5 — —
Vd (mL) Preop 136.7 ± 5.1 270.0 ± 14.0 195.5 ± 17.6 223.9 ± 24.9 128.0 ± 17.0
Postop 120.5 ± 4.5* 145.5 ± 9.5‡ 144.0 ± 15.3 151.0 ± 18.3* 108.0 ± 11.0
Vs (mL) Preop 58.0 ± 4.1 113.8 ± 9.6 99.5 ± 10.9 88.8 ± 16.1 54.9 ± 6.8
Postop 50.3 ± 3.8 55.1 ± 7.6‡ 74.7 ± 13.5 66.7 ± 15.9 48.9 ± 9.1
SV (mL) Preop 79.1 ± 2.8 161.0 ± 10.7 95.9 ± 9.7 134.4 ± 14.3 80.8 ± 13.4
Postop 72.2 ± 2.2 89.6 ± 6.4‡ 77.9 ± 6.1 71.5 ± 5.4* 56.5 ± 4.1
EF (%) Preop 61 ± 2 60 ± 2 50 ± 3 62 ± 3 60 ± 3
Postop 61 ± 1 63 ± 2 54 ± 4 56 ± 6* 57 ± 4
LVM (g) Preop 361.3 ± 22.6 452.3 ± 41.6 — — —
Postop 265.5 ± 12.6† 276.2 ± 25.5* — — —
LVMI (g/m2) Preop 201.3 ± 12.5 247.7 ± 12.3 — — —
Postop 148.7 ± 6.4† 146.6 ± 11.7* — — —
NYHA, New York Heart Association functional class; AR, aortic regurgitation; MR, mitral regurgitation; Mitral T 0.5, mitral gradient half-time; RVp, systolic right
ventricular pressure; LVd, left ventricular diastolic dimension; LVs, left ventricular systolic dimension; LA, left atrial dimension; IVS, interventricular septum dimen-
sion; PW, posterior wall dimension; LVET, left ventricular ejection time; a/H ratio, atrial/total apex cardiographic height; Vd, diastolic volume; Vs, systolic volume;
SV, stroke volume; EF, ejection fraction; LVM, left ventricular mass; LVMI, left ventricular mass index. Numbers denote patients with echocardiographic investiga-
tions at follow-up. Different variables are available in fewer cases.
*P < .05.
†P < .01.
‡P < .001.
Patients were regarded as having normal prosthetic function
if the prosthetic leakage was grade 2/4 or less and the peak
gradient was 60 mm Hg or less for aortic bioprostheses and
15 mm Hg or less for mitral bioprostheses. 
Results
We present data for those with normal bioprosthetic
function (group A), those with abnormal bioprosthetic
function (group B), and those requiring reoperation
(group C). 
Group A: Normal bioprosthetic function. A total
of 274 patients displayed normal bioprosthetic function
echocardiographically. Table II shows the measure-
ments before and after the operation among these
patients, stratified in groups according to the preopera-
tive diagnoses among those with aortic (n = 242) or
mitral (n = 33) bioprostheses.
In the group with aortic bioprostheses, the mean
functional class improved from 2.8 before operation to
1.6 at follow-up. The reduction in maximum gradient
was 67 mm Hg in patients with an aortic stenosis and
28 mm Hg with mixed aortic lesions, whereas it was
unchanged with aortic regurgitation. There was a rela-
tionship between prosthetic size and transvalvular gradi-
ent, with a higher gradient for size 21 prostheses (Fig 2). 
Right ventricular pressure was reduced to a normal or
slightly elevated level. The left ventricular dimension
was reduced by valve replacement to a normal, average
level in all groups, with the most marked decrease, 1.7 cm
in diastole and 1.3 cm in systole, among those with pre-
operative aortic regurgitation. The left atrial dimension
did not change significantly. Among patients with pre-
operative aortic stenosis, there was a marked reduction
in wall thickness—4 mm for the interventricular sep-
tum and 3 mm for the posterior wall. Despite an
unchanged ejection fraction, the left ventricular ejec-
tion time was reduced by approximately 15% in all
groups, which meant that the resistance to ejection or
the amount of blood to be ejected for each beat was
reduced, thus enabling ejection to be finished earlier.
Left ventricular distensibility tended to improve
according to the apex cardiographic a/H ratio. The left
ventricular diastolic volume decreased in all groups,
although the decrease was most marked in aortic regur-
gitation. In this group, systolic volume and stroke vol-
ume were both reduced to about 50% of the preopera-
tive values. Left ventricular mass and mass index were
reduced by valve replacement in both aortic stenosis
(by 26%) and regurgitation (by 41%). We found no
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Fig 2. Aortic bioprostheses in the group specified as
having normal bioprosthetic findings. Mean values for
maximum gradients in relation to valve size.
Fig 3. Distribution of ejection fractions in each functional
class (New York Heart Association) for patients with normal
aortic bioprostheses.
relationship between functional class and ejection frac-
tion at follow-up (Fig 3). 
Among patients with mitral bioprostheses, the func-
tional class improved from a preoperative mean value
of 3.0 to 1.8 at the latest follow-up. Patients with mitral
lesions had a transprosthetic gradient of 12 to 13 mm Hg
at follow-up (Table II). There was no consistent rela-
tionship between the size of the prosthetic valve and
gradient (Fig 4). The mean right ventricular pressure
was similar in both categories of preoperative mitral
lesions and approximately 20 mm Hg higher than in
aortic stenosis or regurgitation, as might be expected.
Mitral valve replacement caused a reduction in right
ventricular pressure of 17 to 20 mm Hg. The left ven-
tricular dimension was enlarged in mitral regurgitation,
and this was reduced by valve replacement. Before the
operation, the left atrium was 2 cm larger than the nor-
mal size, and valve replacement caused a nonsignifi-
cant reduction of 4 to 7 mm. Stroke volume, including
regurgitant volume, was reduced by almost 50% in the
patient group with regurgitation. We found no relation-
ship between functional class and ejection fraction at
follow-up (Fig 5). 
Group B: Abnormal bioprosthetic function. Indi-
vidual data for the patients with abnormal Doppler
echocardiographic data are presented in Table III for
those with aortic bioprostheses and in Table IV for
those with mitral bioprostheses. As can be seen in
Table III, only 1 patient had a mean aortic gradient of
above 45 mm Hg, and this was also the only patient in
functional class IV. His condition was considered by
the local hospital to be inoperable and he was not reop-
erated on. Severe regurgitation (grade 3/4) was present
in 4 patients. None of the patients with an available
ejection fraction had a value lower than 50%. 
Table IV presents the data for each of the 9 patients
with any suggestion of bioprosthetic problems in the
mitral group. One of the patients had definite signs of
bioprosthetic stenosis, and 4 other patients had a low
ejection fraction. Two patients had a large left ventricle
(7.0 and 7.5 cm) without significant mitral or tricuspid
regurgitation. 
The mean (median) time that elapsed from operation
until echocardiography was 51 (54) versus 56 (49)
months among those with normal and abnormal aortic
bioprostheses and 67 (69) versus 85 (86) months among
those with normal and abnormal mitral bioprostheses.
In neither case did the time from operation to echocar-
diography differ significantly between those judged as
normal and those judged as abnormal. Consequently,
there were weak correlations between time to echocar-
diography (days) and maximum gradient (r = –0.012,
no significant relationship), regurgitation grade (r = 0.15,
P = .02), and estimation of leaflet calcifications in 2-
dimensional echocardiography (r = 0.19, P = .02). The
correlations were somewhat higher between estimated
calcification and aortic regurgitation (r = 0.26, P = .001)
and maximum gradient (r = 0.39, P < .0001). The pos-
sible influence on aortic prosthetic valve gradient was
further evaluated in a multivariate analysis. Valve size
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Fig 4. Normal mitral bioprostheses. Mean values for maxi-
mum gradients in relation to valve size.
Fig 5. Distribution of ejection fractions in each functional
class (New York Heart Association) for patients with a nor-
mal mitral bioprosthesis.
(P < .0001), body surface area (P < .01), and age (P <
.01) contributed to the explanation of maximum gradi-
ent, whereas time to echocardiography did not. When
groups of valve sizes were being evaluated, a positive
correlation was noted between time to echocardiogra-
phy and prosthetic valve gradient in the groups with a
large (‡ size 29) prosthesis (r2 = 0.29, P < .05), whereas
no relation was seen among those with smaller pros-
thetic valves. 
Group C: Reoperations. In all, 51 patients were
reoperated on during the 10-year period. Most of them
were followed up repeatedly with Doppler echocardiog-
raphy before the reoperation.
Forty-one patients with aortic bioprostheses were reop-
erated on (Table V). Twenty-seven of these (mean age
55.6 years) had structural valve deterioration, with calci-
fication or stiffness in the cusps or cusp rupture. Six
patients with paravalvular leakage were reoperated on, as
were 8 patients with prosthetic valve endocarditis. The
initial bioprosthesis lasted on average 45.3 months. In
only 4 of 27 cases of structural valve deterioration was
the reoperation performed within a shorter time than 4
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Table III. Abnormal aortic bioprosthetic valves (n = 21)
Follow-up Valve Maximum Mean NYHA 
time Age Diagnosis size LVd EF gradient gradient AR MR function 
(mo) (yr) preop (mm) (cm) (%) (mm Hg) (mm Hg) (grade) (grade) class
4 62 AS + CAD 23 4.9 87 63 37 0.5 0.5 II
5 73 AR 21 4.8 73 65 36 0.5 0.5 III
20 60 AS 23 5.4 61 84 — 2.5 1 II
22 73 AS 23 5.4 73 70 — 2 1 III
23 76 AS 23 4.6 58 28 12 3 1.5 II
23 76 AS 23 4.6 75 66 32 2 0.5 I
26 70 AM 23 5.2 75 64 43 0.5 0.5 I
36 50 AS 23 — — 70 40 2 — I
42 70 AS + CAD 25 6.1 69 46 23 3 2 I
46 67 AS 23 — — 87 — 1 1 II
49 72 AS 23 6.5 57 63 36 0.5 0.5 I
64 73 AS + CAD 25 5.6 65 90 60 3 0.5 IV
68 67 AM 23 — — 72 — 1 — I
78 75 AM 25 7.2 52 70 21 3 — II
83 67 AS 25 — — 25 10 2.5 0.5 III
85 62 AM 25 4.9 64 78 32 1 — II
91 39 AS 27 4.8 — 80 — — 0.5 II
97 75 AS + CAD 23 5.1 62 67 35 1 0 I
98 25 AR 21 4.7 — 68 44 1 0.5 I
104 56 AR 25 6.5 57 27 17 2.5 0 II
124 55 AM 25 5.6 62 20 — 2.5 0 II
AR, Aortic regurgitation; AS, aortic stenosis; AM, aortic mixed lesion; CAD, coronary artery disease; LVd, left ventricular diastolic dimension; EF, ejection fraction;
MR, mitral regurgitation; NYHA, New York Heart Association.
Table IV. Abnormal mitral bioprosthetic valves (n = 9)
Follow-up Valve Max Mitral NYHA 
time Age Diagnosis size LVd LA gradient T 0.5 EF MR TR RVp function 
(mo) (yr) preop (mm) (cm) (cm) (mm Hg) (ms) (%) (grade) (grade) (mm Hg) (class)
59 29 MR 27 7.5 4.7 18 175 30 0.5 0.5 — I
76 62 MS 33 5.0 8.3 22 275 68 0 2.5 60 II
85 32 MS 29 4.2 4.4 16 100 60 0 0 — I
86 69 MS + CAD 25 7.0 4.9 25 73 — 0 1 — III
89 66 MR 29 3.9 4.4 16 165 33 0 1 27 II
89 51 MM 33 5.4 5.2 27 100 61 3 0 — III
96 53 MS 27 4.2 5.8 18 100 82 2.5 3.5 50 III
96 53 MM 25 5.1 3.5 19 175 72 1.5 1.5 47 II
101 34 MS 33 5.6 5.2 25 57 67 3.5 0 — II
MR, Mitral regurgitation; MS, mitral stenosis; MM, mitral mixed lesion; CAD, coronary artery disease; LVd, left ventricular diastolic dimension; LA, left atrial dimen-
sion; EF, ejection fraction; T 0.5, gradient half-time; TR, tricuspid regurgitation; RVp, right ventricular systolic pressure; NYHA, New York Heart Association. 
months from the first echocardiographic detection, with
just 1 patient undergoing an emergency reoperation. The
average time from the detection of an abnormality in the
bioprosthesis until the reoperation was performed was
1.5 years. This contrasts with the time frame for those
with paravalvular leakage and even more strongly with
that for those with prosthetic valve endocarditis.
However, the time interval from the initial operation to
reoperation for those patients with paravalvular leakage
was almost 2 years (23.6 months), and for those reoper-
ated on due to prosthetic valve endocarditis it was 35
months. Actuarial analysis (Cox) did not show any dif-
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Table V. Aortic bioprostheses necessitating reoperation (n = 41)
Doppler before reop
Duration of Maximum Time interval/
implantation Age gradient first detection to reop 
(mo) (yr) (mm Hg) AR (grade) (mo) Operative findings
Structural valve deterioration (n = 27)
4 76 45 3 1 Cusp rupture
11 64 Normal 2.5 5 No major findings
11 66 63 1.5 4 Paravalvular leak/cusp rupture
12 65 15 2.5 5 Calcification/minor cusp rupture
12 55 76 3 10 Paravalvular leak/minor cusp rupture
12 70 Normal 3.5 2 Cusp rupture
20 50 41 3 16 Paravalvular leak/minor cusp rupture
22 35 65 3 2 Cusp rupture
24 74 49 0 8 No major findings
28 64 92 2.5 17 Cusp rupture
34 64 20 3.5 6 Paravalvular leak/minor cusp rupture
38 68 50 0.5 6 Valve stiffness
40 64 Normal 3 24 Paravalvular leak/minor cusp rupture
42 47 64 3 27 Calcification/minor cusp rupture
43 56 Normal 2.5 41 Cusp rupture
45 72 Normal 2 7 Cusp rupture
48 60 Normal 2.5 4 Cusp rupture
55 35 80 3.5 6 Calcification/cusp rupture
65 70 21 2.5 56 Paravalvular leak/minor cusp rupture
69 34 52 4 0 Calcification/cusp rupture
69 55 47 2.5 16 Paravalvular leak/minor cusp rupture
72 39 37 3 21 Minor cusp rupture
76 43 Normal 2 36 Minor cusp rupture
79 64 27 3 4 Calcification
91 59 19 2* 12 Cusp rupture
91 20 Normal 3 12 Calcification/cusp rupture 
109 31 93 2 52 Calcification
Nonstructural valve dysfunction (n = 6)
1.5 34 30 3 1 Paravalvular leak
13 66 Normal 3 6 Paravalvular leak
16 62 35 3 8 Paravalvular leak
24 65 23 3.5 9 Paravalvular leak
39 28 Normal 4 0.5 Paravalvular leak
48 45 60 4 14 Paravalvular leak
Prosthetic valve endocarditis (n = 8)
10 32 — 4 0 Paravalvular leak/aneurysm
24 72 49 0.25 0 Vegetations
25 33 Normal 2.5 0 Paravalvular leak/aneurysm
32 42 61 0.5 0 Vegetations/paravalvular leak
32 41 85 2 24 “Cold” abscess
47 71 — † 0 Cusp vegetations
50 51 50 4 4 Cusp destruction
60 36 Normal 4 0 Cusp vegetations
*Severe aortic regurgitation. 
†The acuteness of the situation did not permit a complete echocardiographic investigation; however, vegetations were found.
ference in reoperations between those with a small (size
21 or 23) prosthetic valve and those with a larger valve.
Most patients (21/27) who were reoperated on
because of structural deterioration in the aortic bio-
prosthesis had a Doppler-determined regurgitation of
greater than grade 2/4, and in only 1 patient was no
leakage detected. At operation, paravalvular leakage,
with some degree of cusp rupture, was detected in 7 of
27 patients, all but 1 with regurgitation of greater than
grade 2/4 before reoperation; the remaining patient had
moderate preoperative regurgitation and increasing left
ventricular dimension. Another 15 of 27 patients were
found to have bioprosthetic cusp rupture at reoperation,
13 with a preoperative regurgitation of greater than
grade 2/4 and 2 with moderate regurgitation and an
increasing left ventricle. In 3 of 27 patients, calcified or
stiff valves were the main operative finding; 2 of these
patients had a preoperative gradient of greater than 60
mm Hg, and the third had a leakage of more than grade
2/4. In 2 of 27 patients (1 with a gradient of > 60 mm Hg
and the other with regurgitation of > grade 2/4), no
major bioprosthetic lesion was detected during reoper-
ation. Because these patients had a gradual deteriora-
tion in heart function before reoperation and an obvious
recovery after reoperation, we characterized them as
valve-dependent. All 6 patients with nonstructural
valve dysfunction had paravalvular leakage at reopera-
tion and severe preoperative regurgitation. The patients
with prosthetic valve endocarditis had cusp vegeta-
tions, destroyed cusps, or an abscess at operation and a
preoperative clinical picture, together with Doppler
echocardiographic findings, indicative of prosthetic
valve endocarditis. 
Ten patients with mitral bioprostheses were reoperat-
ed on during the follow-up period because of structur-
al valve deterioration with a high gradient (n = 3), non-
structural dysfunction with severe paravalvular leakage
(n = 3), or prosthetic valve endocarditis with vegeta-
tions (n = 4) (Table VI). The mean age of the patients
reoperated on because of structural valve deterioration
was 46 years and the mean time from the implantation
of a mitral bioprosthesis until reoperation for structural
valve deterioration was 79 months. As was the case for
the patients with aortic bioprostheses who were reoper-
ated on because of prosthetic valve endocarditis,
almost all (3/4) those with mitral endocarditis required
an emergency operation. Patients with nonstructural
dysfunction all displayed paravalvular leakage at reop-
eration and a corresponding severe preoperative regur-
gitation. The findings were also convincing among the
patients with prosthetic valve endocarditis.
Discussion
The results of this study demonstrate that almost all
the patients (92%) without findings leading to reopera-
tion had normal valve function as measured by
transthoracic Doppler echocardiography. However, this
extrapolation is associated with some uncertainty, be-
cause echocardiography was not performed in all
patients. Despite the facts that some patients were not
evaluated by echocardiography and the noninvasive
investigations were not randomized, the only likely
selection bias was over-representation of younger ages
and atrial fibrillation among those having an investiga-
tion. If anything, this factor should have helped to
emphasize valve function problems, because we have
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Table VI. Mitral bioprostheses necessitating reoperation (n = 10)
Doppler before reop
Duration of Maximum Time interval/ 
implantation Age gradient MR first detection until reop Operative 
(mo) (yr) (mm Hg) (grade) (mo) findings
Structural valve deterioration (n = 3)
60 58 25 0 1 Calcification
84 45 21 3.5 3 Cusp rupture
93 35 25 0.5 18 Calcification
Nonstructural valve dysfunction (n = 3)
2 79 — 3 1 Paravalvular leak
28 64 16 4 2 Paravalvular leak
41 64 16 3 10 Paravalvular leak
Prosthetic valve endocarditis (n = 4)
4 50 * — 0 Vegetations
12 73 12 3 0.5 Paravalvular leak
12 73 * — 0 Vegetations
43 31 * 0 0 Vegetations
*The acuteness of the situation did not permit complete echocardiographic investigations; however, vegetations were found. 
previously found in the same cohort that lower age is
associated with a worse outcome.6,7 We therefore be-
lieve that the functional results presented in this study
are representative of the total group undergoing valve
replacement with a bioprosthesis. 
Doppler echocardiographic functional assess-
ment. We were not able to find any correlation between
functional class (New York Heart Association) and
ejection fraction (Figs 3 and 5). Inasmuch as the
patients have estimated their own functional class, the
assessment is obviously not merely based on physical
capability but is probably also influenced by psycho-
logic factors. However, even the relationship between
objectively measured exercise capacity and ejection
fraction is low or lacking among patients with conges-
tive heart failure.15
Our normal mitral Doppler gradients are concordant
with the data reported by Alam and colleagues.16 In
patients with aortic bioprostheses, these authors found
a somewhat lower transprosthetic gradient than we did;
however, our data are identical with those reported by
Eriksson and associates17 and compare well with re-
view data of earlier reports.18 In accordance with pre-
vious findings of an inverse relationship between valve
size and gradient in aortic prostheses,19 the peak gradi-
ent with a size 21 aortic bioprosthesis was higher than
that of size 23 or larger valves. 
Valve replacement caused both a hemodynamic im-
provement in valve function and improved left ventric-
ular function. The diastolic left ventricular cavity
dimension and volume decreased in all groups apart
from mitral stenosis. Another beneficial and anticipat-
ed finding was a reduction in the thicknesses of the sep-
tal and posterior walls in patients with aortic stenosis,
with normalization of diastolic function as measured
by the apex cardiographic a/H ratio. 
We considered prosthetic regurgitation of more than
grade 2/4 or a maximum aortic gradient of more than
60 mm Hg or a mitral gradient of more than 15 mm Hg
to be putatively abnormal, and the individual data for
such patients are therefore presented separately. The
limit for causing suspicion of a malfunction can be dis-
cussed and lower, but increasing, gradients or leakages
may be taken as warning signs. Most patients of this
type are likely to require a future reoperation. However,
in the early postoperative phase, an intraventricular
increase in flow velocity may increase the estimated
prosthetic gradient20 and, in patients with an outflow
tract velocity of above 1.5 m/s, the correction of the
Doppler calculation of maximum gradient may be jus-
tified.21 Among our patients regarded as having poten-
tially abnormal function of their bioprosthesis accord-
ing to Doppler echocardiography, there was only a
nonsignificant tendency toward longer time from oper-
ation to the echocardiographic evaluation. Prosthetic
valve age did not explain valve gradient in a multi-
variate analysis, whereas size of the valve as well as
size and age of the patient contributed significantly.
Thus other factors than time contribute to valvular
deterioration, and the weak correlation between bio-
prosthetic age and Doppler echocardiographic findings
indicates a low risk that a high proportion of valves
should fail after a certain time period. Time to reopera-
tion also varied considerably (Table V). 
Evaluation of candidates for reoperation. Re-
operations cannot be avoided with any type of biopros-
thetic valve. An early Doppler echocardiographic inves-
tigation is therefore recommended for future
comparisons when prosthetic valve malfunction is sus-
pected.22 When a high gradient or an abnormal leakage
is found, it is important to conduct repeated investiga-
tions; the appropriate time interval is dependent on the
severity of the findings. Thereby, only 1 of our patients
had to be reoperated on on an emergency basis because
of valve deterioration. As has previously been claimed
by others,23,16 we received valuable information from the
single or serial echocardiographic investigations per-
formed before reoperation, with good correspondence to
the intraoperative findings. Nowadays we apply not only
transthoracic but also transesophageal echocardiography
in cases of acute endocarditis or suspected prosthetic
valve dysfunction, and these methods were also in some
cases used to describe the findings among our patients
who underwent reoperation. Transesophageal echocar-
diography can be used for an evaluation of the aortic
valve,24 but its greatest potential and value is in the eval-
uation of malfunctioning mitral valves, particularly for
paravalvular regurgitation.25,26 It is highly recommended
that transesophageal echocardiography be performed in
cases of suspected prosthetic valve malfunction and neg-
ative transthoracic investigation.27,28
Conclusions
Most of the patients (275/305, 90%) had a biopros-
thesis that functioned well, as determined by echocar-
diography in a majority of patients and clinical absence
of important symptoms in the remaining patients. A
small number of patients (30/305, 10%) had abnormal-
ities in their biologic valves, possibly necessitating
reoperation in the future. In the subgroup of patients
who had already undergone reoperation, the preoperative
Doppler echocardiographic investigations corresponded
almost completely to the intraoperative findings.
Bioprosthetic abnormalities in terms of calcification or
cusp rupture (or both) and their hemodynamic conse-
quences develop gradually and can be monitored safely
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by Doppler echocardiography to choose the optimum
time for reoperation. 
We appreciate the performance of Doppler echocardio-
graphic evaluations by the staff at the Departments of Clinical
Physiology and Medicine at the hospitals in western Sweden
and in particular the Borås, Mölndal, Norra Älvsborg,
Sahlgrenska, Skövde, Uddevalla, Varberg, Örebro, and Östra
Hospitals.
R E F E R E N C E S
1. Bortolotti U, Milano A, Mazzaro E, Thiene G, Talenti E, Casarotto
D. Hancock II porcine bioprosthesis: excellent durability at inter-
mediate-term follow-up. J Am Coll Cardiol 1994;24: 676-82.
2. Burdon TA, Miller DC, Oyer PE, Mitchell RS, Stinson EB,
Starnes VA, et al. Durability of porcine valves at fifteen years in
a representative North American patient population. J Thorac
Cardiovasc Surg 1992;103:238-52.
3. Cohn LH, Collins J, DiSesa VJ, Couper GS, Peigh GS, Kowalker
W, et al. Fifteen year experience with 1678 Hancock porcine bio-
prosthetic heart valve replacements. Ann Surg 1989;210:435-43.
4. Jamieson WRE, Allen P, Miyagishima RT, Gerein AN, Munro AI,
Burr LH, et al. The Carpentier-Edwards standard porcine bio-
prosthesis: a first generation tissue valve with excellent long-term
clinical performance. J Thorac Cardiovasc Surg 1990;99:543-61.
5. Jones EL, Weintraub WS, Craver JM, Guyton RA, Cohen CL,
Corrigan VE, et al. Ten-year experience with the porcine bio-
prosthetic valve: interrelationship of valve survival and patient
survival in 1,050 valve replacements. Ann Thorac Surg 1990;
49:370-84.
6. Mykén P, Caidahl K, Larsson S, Berggren H. Ten-year experience
with the Biocor porcine bioprosthesis in the aortic position. J
Heart Valve Dis 1994;3:648-56.
7. Mykén P, Caidahl K, Larsson S, Berggren H. Ten-year experience
with the Biocor porcine bioprosthesis in the mitral position. J
Heart Valve Dis 1995;4:63-9.
8. Magilligan DJ Jr, Lewis JW, Stein P, Alam M. The porcine bio-
prosthetic heart valve: experience at 15 years. Ann Thorac Surg
1989;48:324-30.
9. Teoh KH, Ivanov J, Weisel RD, Daniel LB, Darcel IC, Rakowski
H. Clinical and Doppler echocardiographic evaluation of bio-
prosthetic valve failure after 10 years. Circulation 1990;82
(Suppl):IV110-6.
10. Barratt-Boyes BG, Jaffe WM, Hong Ko P, Whitlock RML. The
zero pressure fixed Medtronic Intact porcine valve: an 8.5 year
review. J Heart Valve Dis 1993;2:604-11.
11. Sahn D, DeMaria A, Kisslo J, Weyman A. Recommendations
regarding quantitation in M-mode echocardiography: results of a
survey of echocardiographic measurements. Circulation 1978;
58:1072-83.
12. Teichholtz L, Kreulen T, Merman M, Gorlin R. Problems in
echocardiographic volume determinations: echocardiographic-
angiographic correlations in the presence or absence of asynergy.
Am J Cardiol 1976;37:7-11.
13. Caidahl K, Eriksson H, Hartford M, Wikstrand J, Wallentin I,
Arvidsson A, et al. Dyspnea of cardiac origin in 67-year-old men:
II. Relation to diastolic left ventricular function and mass. The
study of men born in 1913. Br Heart J 1988;59:329-38.
14. Waagstein F, Caidahl K, Wallentin I, Bergh C-H, Hjalmarson Å.
Long-term b -blockade in dilated cardiomyopathy: effects of
short- and long-term Metropolol treatment followed by with-
drawal and readministration of Metropolol. Circulation 1989;80:
551-63.
15. Franciosa J, Levine T. Lack of correlation between exercise
capacity and indexes of resting left ventricular performance in
heart failure. Am J Cardiol 1981;47:33-9.
16. Alam M, Rosman HS, Lakier JB, Kemp S, Khaja F, Hautamaki
K, et al. Doppler and echocardiographic features of normal and
dysfunctioning bioprosthetic valves. J Am Coll Cardiol 1987;10:
851-8.
17. Eriksson M, Brodin L-Å, Ericsson A, Lindblom D. Doppler-
derived pressure differences in normally functioning aortic valve
prostheses. Scand J Thorac Cardiovasc Surg 1993;27:93-7.
18. Reisner SA, Meltzer RS. Normal values of prosthetic valve
Doppler echocardiographic parameters: a review. J Am Soc
Echocardiogr 1988;1:201-10.
19. Cooper DM, Stewart RW, Schiavone WA, Lombardo HP, Lytle
BW, Loop FD, et al. Evaluation of normal prosthetic valve func-
tion by Doppler echocardiography. Am Heart J 1987;114:576-
82.
20. Wiseth R, Skjaerpe T, Hatle L. Rapid systolic intraventricular
velocities after valve replacement for aortic stenosis. Am J
Cardiol 1993;71:944-8.
21. Wilkins G, Flachskampf F, Weyman A. Echo-Doppler assessment
of prosthetic heart valves. In: Weyman A, editor. Principles and
practice of echocardiography. Philadelphia: Lea & Febiger; 1994.
p. 1198-230.
22. Panidis IP, Ross J, Mintz GS. Normal and abnormal prosthetic
valve function as assessed by Doppler echocardiography. J Am
Coll Cardiol 1986;8:317-26.
23. Forman B, Phelan B, Robertson R, Virmani R. Correlation of
two-dimensional echocardiography and pathologic findings in
porcine valve dysfunction. J Am Coll Cardiol 1985;5:224-30.
24. Dittrich HC, McCann HA, Walsh TP, Blanchard DG, Oppenheim
GE, Waack TC, et al. Transesophageal echocardiography in the
evaluation of prosthetic and native aortic valves. Am J Cardiol
1990;66:758-61.
25. Alam M, Serwin JB, Rosman HS, Polanco GA, Sun I, Silverman
NA. Transesophageal echocardiographic features of normal and
dysfunctioning bioprosthetic valves. Am Heart J 1991;121:1149-55.
26. Chaudhry FA, Herrera CJ, DeFrino PF, Mehlman DJ, Zabalgoitia
M. Pathologic and angiographic correlations of transesophageal
echocardiography in prosthetic heart valve dysfunction. Am
Heart J 1991;122:1057-64.
27. Daniel WG, Mügge A, Grote J, Hausman D, Nikutta P, Laas J, et
al. Comparison of transthoracic and transesophageal echocardio-
graphy for detection of abnormalities of prosthetic and biopros-
thetic valves in the mitral and aortic positions. Am J Cardiol.
1993;71:210-5.
28. Zabalgoitia M, Herrera CJ, Chaudry FA, Calhoon JH, Mehlman
DJ, O´Rourke RA. Improvement in the diagnosis of bioprosthetic
valve dysfunction by transesophageal echocardiography. J Heart
Valve Dis 1993;2:595-603.
608 Mykén et al The Journal of Thoracic and
Cardiovascular Surgery
October 1998
